Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice

Future Virology

Volumn 8, Issue 11, 2013, Pages 1085-1094

  Smee, Donald F ^a   Tarbet, E Bart ^a   Furuta, Yousuke ^b   Morrey, John D ^a   Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

antiviral; drug combination; drug resistance; favipiravir; H1N1; influenza; mice; oseltamivir; T 705; treatment

Indexed keywords

FAVIPIRAVIR; OSELTAMIVIR; PLACEBO;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84886683780     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.98     Document Type: Article

References (35)

1. Mossad SB. The resurgence of swine-origin influenza A (H1N1). Cleve. Clin. J. Med 76(6), 337-343 (2009).
2. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196(2), 249-257 (2007).
3. Hata M, Tsuzuki M, Goto Y et al. High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005-2006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR. Jpn J. Infect. Dis. 60(4), 202-204 (2007).
4. Govorkova EA, Baranovich T, Seiler P et al. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res. 98(2), 297-304 (2013).
5. Hall RJ, Peacey MP, Ralston JC et al. Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir. Euro. Surveill. 14(30), 19282 (2009).
6. Rungrotmongkol T, Intharathep P, Malaisree M et al. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem. Biophys. Res. Commun. 385(3), 390-394 (2009).
7. Gubareva LV, Trujillo AA, Okomo-Adhiambo M et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir. Ther. 15, 151-159 (2010).
8. Besselaar TG, Naidoo D, Buys A et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 14(1), 1809-1810 (2008).
9. Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301(10), 1034-1041 (2009).
10. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15(4), 552-560 (2009).
11. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: A systematic review of systematic reviews. PLoS ONE 8(4), e60348 (2013).
12. Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46(4), 977-981 (2002).
13. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51(3), 845-851 (2007).
14. Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl Acad. Sci. USA 107(2), 882-887 (2010).
15. Smee DF, Hurst BL, Wong MH et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 54(1), 126-133 (2010).
16. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49(3), 981-986 (2005).
17. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza And 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54(6), 2517-2524 (2010).
18. Govorkova EA, Webster RG. Combination chemotherapy for influenza. Viruses 2, 1510-1529 (2010).
19. Nguyen JT, Smee DF, Barnard DL et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS ONE 7(1), e31006 (2012).
20. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 94(1), 103-10 (2012).
21. Carrat F, Duval X, Tubach F et al. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir. Ther. 17(6), 1085-1090 (2012).
22. Escuret V, Cornu C, Boutitie F et al Oseltamivir-zanamivir bitherapy compared with oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral Res. 96(2), 130-137 (2012).
23. Seo S, Englund JA, Nguyen JT et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: Safety and pharmacokinetics. Antivir. Ther. 18(3), 377-386 (2013).
24. Smee DF, Julander JG, Tarbet EB, Gross M, Nguyen J. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. Antiviral Res. 96(1), 13-20 (2012).
25. Ilyushina NA, Khalenkov AM, Seiler JP et al. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 84(17), 8607-8616 (2010).
26. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-498 (1938).
27. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53(5), 2120-2128 (2009).
28. Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14(4-5), 181-205 (1990).
29. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52(1), 3889-3897 (2008).
30. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55(2), 307-317 (2002).
31. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54(2), 79-88 (2002).
32. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 70(3), 121-131 (2006).
33. Oxford JS, Logan IS, Potter CW. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 226(5240), 82-83 (1970).
34. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 193(6), 765-772 (2006).
35. Baranovich T, Wong SS, Armstrong J et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87(7), 3741-3751 (2013).